You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微創醫療(00853.HK)年度收入7.79億美元 同比增長20%

格隆匯3月31日丨微創醫療(00853.HK)發佈年度業績公吿,2021年實現收入7.79億美元,同比增長20.0%;公司權益股東應占虧損2.76億美元,同比擴大44.57%;基本每股虧損15.29美分。報吿期內,集團錄得收入較2020年增加20.0%(按美元計),或增加15.0%(剔除匯率影響)。心律管理業務及骨科醫療器械業務分別錄得剔除匯率影響後收入增長18.8%及5.1%,該增長主要歸因於新型冠狀病毒疫情恢復帶來的擇期手術量的回升。得益於快速市場推廣及新產品上市,心臟瓣膜業務、神經介入產品業務以及大動脈及外周血管介入產品業務仍然保持快速增長,分別錄得剔除匯率影響後收入增長93.2%,72.5%及45.6%。

2021年度,集團錄得虧損3.513億美元(公司權益股東應占虧損:2.765億美元),而2020年度則錄得虧損2.233億美元(公司權益股東應占虧損:1.913億美元)。該變動主要歸因於手術機器人業務、心臟瓣膜等業務藉助獨立融資渠道,積極推進研發、註冊、商業化等帶來費用的增加;用於海外市場開拓、產品推廣等投入增加;報吿期內根據集團股份獎勵計劃對若干僱員授予激勵股票所確認的成本增加;冠脈支架中國集中帶量採購政策帶來的影響;新發行的可換股債券的應計利息;及心臟瓣膜、手術機器人及神經介入產品業務的首次公開發售費用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account